The effects of long-term treatment of streptozotocin-diabetic rats with an aldose reductase inhibitor.
To test the possible involvement of the sorbitol pathway in the pathogenesis of retinopathy in long-term experimentally-diabetic rats, streptozotocin-diabetic and normal rats were dosed orally (50 mg/kg body weight daily) for up to 373 days with an aldose reductase inhibitor (ICI 105552) or a placebo. Long-term treatment with ICI 105552 (1,(3,4-dichlorobenzyl)-3-methyl-1,2-dihydro-2-oxoquinol-4-ylaceti c acid; sodium salt) markedly reduced the normal accumulations of sorbitol and fructose in the sciatic nerves (86 and 69% reductions) and seminal vesicles with coagulating glands (75 and 49% reductions). Thus, by these criteria, the inhibitor was as effective after several months of dosing as after three weeks. There was no evidence that treatment with this aldose reductase inhibitor had any protective effect against the development of pathological changes in the retina and kidney of these rats.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005632:Fructose / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D007668:Kidney / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011804:Quinolines / Q000627:therapeutic use*; D015363:Quinolones; D051381:Rats; D011919:Rats, Inbred Strains; D012160:Retina / Q000473:pathology; D013012:Sorbitol / Q000378:metabolism; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*; D013997:Time Factors
D011804:Quinolines; D015363:Quinolones; D005632:Fructose; D013012:Sorbitol; C033661:ICI 105552; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase; D005947:Glucose